Worldwide, colorectal cancer is the third most common incident cancer and the fourth leading cause of cancer death, with 1·4 million new cases and 700 000 deaths estimated in 2012-most of these from the developed world.
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In The Lancet, Wendy Atkin and colleagues 4 report on the extended follow-up of the UK Flexible Sigmoidoscopy Screening Trial (UKFSST) through a median of 17 years of follow-up. This randomised controlled trial enrolled 170 432 eligible men and women to either an intervention group (off ered one-time fl exible sigmoidoscopy screening) or control group (not contacted), with primary outcomes of colorectal cancer incidence and mortality. The analysed cohort included 57 098 people in the intervention group, of whom 40 621 (71%) received screening, and 112 936 people in the control group. A previous report of 11 years of follow-up reported hazard ratios (HRs) in intention-to-treat (ITT) analyses of 0·77 (95% CI 0·70-0·84) for colorectal cancer incidence and 0·69 (0·59-0·82) for colorectal cancer mortality for the intervention versus control group. 5 Rather remarkably, because the trial used only one fl exible sigmoidoscopy screen at baseline, these HRs were maintained through an additional 6 years, with ITT HRs now of 0·74 (95% CI 0·70-0·80) for incidence and 0·70 (0·62-0·79) for mortality. 4 These new results are important for two reasons. First, and especially with regards to the reported reduction in incidence of distal colorectal cancer, the implications for our understanding of the natural history of adenomas and colorectal cancer are intriguing. Second, the reported reduction in incidence and mortality of overall colorectal cancer provides needed data from a public health perspective on the optimal design of a screening programme that incorporates fl exible sigmoidoscopy.
Because of ethical concerns in leaving colon polyps intact for appreciable time periods, the natural history of adenomas, especially with regards to quantitative transition rates to colorectal cancer, is largely unknown. 6 Estimates of transition rates and intervals largely derive from modelling studies, which generally rely on data covering only short periods of observation (5-10 years). 7 The fi ndings of Atkin and colleagues' extended followup should inform future modelling eff orts and lead to a better understanding of the natural history of adenoma.
Based on the per-protocol analysis of Atkin and colleagues of the eff ectiveness in participants who received fl exible sigmoidoscopy screening, the reduction in incidence for distal colorectal cancer was actually slightly greater at 17 years of follow-up (HR 0·44 [95% CI 0·38-0·50]) 4 than at 11 years (0·50 [95% CI 0·42-0·59]). 5 After exclusion of prevalent cases, and with the assumption that the rate of such cases was the same in the control group as in those actually screened (126 [0·31%] of 40 621), a per-protocol analysis would show a striking 66% reduction in the incidence of distal colorectal cancer over 17 years. With the exception of the small subset referred for surveillance colonoscopy, this prevention was all due to a single fl exible sigmoidoscopy screen at baseline. These fi ndings suggest that the rate at which de-novo adenomas formed and transitioned to symptomatic colorectal cancer within 17 years was quite low. Current models of the natural history of adenoma should be reassessed to see if they are consistent with these long-term results. The trial protocol called for surveillance colonoscopy for patients found to be at high risk on the baseline screen. Of the 40 621 people actually screened, 1745 (4%) were reported to have undergone surveillance. 5 Additional information about this surveillance cohort in terms of yield of adenomas and colorectal cancer over time would be useful to understand the various components of the sustained incidence reduction.
From a public health perspective, the updated fi ndings of a reduction in the overall colorectal cancer incidence and mortality through to 17 years raises the issue of whether once-only fl exible sigmoidoscopy might be a reasonable screening strategy. Outside of the USA, where colonoscopy is the primary method of colorectal cancer screening, 8 colorectal cancer screening guidelines generally recommend either fl exible sigmoidoscopy or stool-based testing, either alone or in combination.
2 However, within this general framework, uncertainty exists regarding several issues, including how (and whether) to combine fl exible sigmoidoscopy with stool testing, starting and stopping ages, and testing intervals. 2 The extended fi ndings of the UKFSST contribute substantively to this conversation, although they do not provide a defi nitive answer.
The current UK national screening programme includes biennial FOBT for people aged 60-74 years and, starting in 2013 and gradually being fully implemented, onetime fl exible sigmoidoscopy at age 55 years. 4 Based on the UKFSST fi ndings, 4 and the absence of a reduction in incidence of colorectal cancer with use of FOBT in most trials, 9 the addition of the FOBT will probably have relatively little eff ect on colorectal cancer incidence, especially distal colorectal cancer. However, the addition of FOBT might well have added benefi t in terms of reducing colorectal cancer mortality, and especially of proximal colorectal cancer type.
In the absence of a subsequent FOBT (or FIT) testing programme, screening programme planners need to assess the probable added benefi t of a second fl exible sigmoidoscopy screen, say 10-15 years after the fi rst. The results of Atkin and colleagues' study suggest that such added benefi t might well be restricted in terms of additional reductions in colorectal cancer incidence or mortality. However, data from continued follow-up of this cohort beyond 17 years, which the investigators state they plan on doing, will further inform this issue.
Additionally, with or without stool testing, another important issue concerns the referral algorithm for colonoscopy. In view of the absence of a signifi cant eff ect on proximal colorectal cancer in the UKFSST, which had a relatively low 5% colonoscopy referral rate, 4 the tradeoff between the additional resource utilisation (and patient harms) of higher referral rates against the greater protection from proximal colorectal cancer needs to be considered. Note that the Prostate, Lung, Colorectal, and Ovarian (PLCO) trial 10 of fl exible sigmoidoscopy showed a signifi cant reduction in incidence of proximal colorectal cancer (relative risk 0·86 [95% CI 0·76-0·97]), although it had a substantially higher colonoscopy referral rate of 21·9% cumulatively over two screening rounds than did the study by Atkin and colleagues. 4 These results from Atkin and colleagues 4 might also be relevant for colonoscopy screening. Although the protection provided by colonoscopy is believed to be less for proximal than for distal colorectal cancer, if these fi ndings were to hold for colonoscopy in a relative sense-ie, if the reduction in incidence of proximal colorectal cancer through to 10 years was found to be maintained through to 17 years or more-it could prompt a re-evaluation of the standard 10 year interval for colonoscopy screening in the USA.
Colorectal cancer is largely a preventable disease. As with cervical cancer, the ability to reduce incidence as well as mortality through minimally invasive removal of precursor lesions is a gift of nature that should be taken advantage of if at all possible. Flexible sigmoidoscopy screening, even once only, is a resource-conserving strategy that, as shown in the study by Atkin and colleagues, seems to achieve much of the potential of colorectal cancer prevention, but one which also misses a substantial fraction of potentially preventable or curable cancers. Assessment of screening strategies involving fl exible sigmoidoscopy, colonoscopy, or stool-testing generally compare screening effi cacy, in terms of colorectal cancer cases or deaths prevented, with the costs and resource utilisations of the screening programme.
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These latest long-term results from the UKFSST should provide additional data for researchers to re-assess these strategies.
